AI

Novartis Benefits From Biotech Lessons Taught By Development Head Aradhye

 
• By 

The Swiss major’s chief medical officer tells Scrip about how “an R&D/commercial continuum” is helping to speed up innovation across the group.

BioFuture Notebook: Struggling With Innovation, Financing And Reimbursement

 

Panels at the recent BioFuture conference focused on the next breakthroughs in areas such as oncology and neurodegenerative diseases, continuing challenges to GLP-1 agonists, financing and how use of AI is taking shape.

AI In Clinical Trials – Big Pharma Execs Outline Journey, Road Ahead

 

Senior executives from GSK, Bayer, Johnson & Johnson and Novartis discuss their experiences and some of the practical aspects of deploying AI in clinical trials. The potential of the technology to fundamentally alter how firms ensure the quality of data was also among the key talking points.

Sanofi Exec On Go-To-Market Models, MLR Reviews, Ambidextrous Leadership

 

Sanofi’s EVP (general medicines), Olivier Charmeil, talks about pharma’s evolving go-to-market strategies that enmesh a more personalized, data-driven approach, why the medical, legal, and regulatory (MLR) review process needs to be faster and also impressive learnings from Amazon, Netflix and Ikea around building customer experience.


Terray Aims To Further Develop AI Platform, Move Into Clinic In 2026

 

The AI-focused biotech closed a $120m series B funding round, bringing the total funding it has raised to $200m, as it aims to have a product candidate in the clinic in 2026.

BIOSECURE Act – Which Indian Firms Are Best Placed To Help Plug Pharma’s Sourcing Gaps?

 
• By 

Indian CMOs, CDMOs and CRDMOs are expanding capacity and making leadership moves ahead of the BIOSECURE Act, anticipating demand from big pharma and budding biotechs. Scrip brings details on leading Indian firms which could be potential go-to suppliers for US companies affected by the proposed Act

AI/ML Alliances May Give Larger Firms Another Edge, S&P Warns

 

All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.

Eight Recent Deals Tapping AI/ML For R&D

 
• By 

Big pharmas, biotechs and the US government look to partner with artificial intelligence and machine learning firms for discovery efforts across therapeutic areas and modalities.


Merck & Co Takes A Punt On Evaxion’s AI Vaccines

 
• By 

Deal Snapshot: Merck likes the look of Evaxion's artificial intelligence-based technology platform to develop immunotherapies and signed a biobucks deal that will help ease the Copenhagen-headquartered biotech's financial situation.

BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps?

 
• By 

Lilly’s Mounjaro to Pfizer’s Paxlovid, the WuXi group has been part of pharma majors’ sourcing chain. How big is the hole clients are to fill when the proposed BIOSECURE Act comes into effect? Here’s a Scrip infographic using Evaluate Pharma data.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

 
• By 

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.

Recursion’s REC-994 Passes Phase II, But Needs To Find Right Dosage, Endpoints For Next Study

 

The study, in cerebral cavernous malformation (CCM), hit the safety primary endpoint and showed signals in efficacy, but analysts pointed out that the bar for success in the disease remains unclear.


GenAI Reality In Pharma Amid Hype, Advances In LLMs For Therapeutics

 

Indegene’s CTO talks to Scrip about the state of GenAI implementations in pharma amid hype and limited clarity on ROI, the need to address foundational issues early on, promising pilots, the firm’s alliance with Microsoft and Google’s generalist LLM for therapeutics.

Quick Listen: Scrip's Five Must-Know Things

 
• By 

In this week's podcast edition of Five Must-Know Things: Narasimhan plays the long game; Merck & Co’s RSV contender; Mounjaro’s China approval; the mid-cap rising stars; and AI could add billions in drug revenues.

McKinsey Exec On Where India Innovation Could Head, Leveraging Pharma’s GCC Ecosystem

 

McKinsey & Company’s senior partner and lead, life sciences practice (Asia), talks to Scrip about innovation niches that could interest Indian firms including the ADC space, using AI to increase confidence in research activities and how India could leverage big pharma’s expanding global capability centres (GCCs) to shape the wider R&D ecosystem.

AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds

 

A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.


McKinsey Finds Global Business Leaders Most Worried About Geopolitics, China Slowdown

 
• By 

Growing geopolitical tensions and a slowing Chinese economy are among the topmost concerns for global business leaders across sectors, a McKinsey study has shown. Separately, in pharma, the BIOSECURE Act continues to occupy centre stage with US House Speaker Johnson recently pledging to push China-targeted legislation before House elections in November

Flagship Plans To Distribute New Fund To About Two Dozen Companies

 

The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.

Parexel Execs On Obesity Drug Hurdles, Parexel GPT, India RWD Opportunity

 
• By 

Parexel’s chief strategy officer Kushal Gohil, Clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India, in the second of this two-part interview with Scrip.

BIO Notebook: Amgen CEO Blasts IRA, Novo Nordisk Stays Cautious On BD, And More

 
• By 

Insights from Day Three of the BIO International Convention in San Diego include Amgen CEO Bob Bradway taking aim at the "Innovation Reduction Act," Novo Nordisk's business development head talking about spending its semaglutide bounty, Roivant's long view on BD prospects for Immunovant's FcRn inhibitor, and more regulatory concerns around artificial intelligence.